全体要約
2020年の療法分野では、オンコロジーが最大シェアを持ち、癌の高い罹患率や革新的な癌薬の市場投入に向けた研究の増加が要因となっています。市場の主要プレーヤーには、米国のLaboratory Corporation of America Holdings、Eurofins Scientific SE、Charles River Laboratories International, Inc.、Evotec SEなどが含まれています。また、アジア太平洋地域は成長率が最も高い地域とされ、政府支出の増加と豊富な患者人口が成長の主要因とされています。
関連する質問
31.4 billion USD (2026)
14.3% (2021 to 2026)
Laboratory Corporation of America Holdings, Eurofins Scientific SE, Charles River Laboratories International, Inc., Evotec SE, WuXi AppTec, Pharmaceutical Product Development LLC, Syngene International Limited, Curia Global Inc., Dr. Reddy Laboratories Ltd. (Aurigene Discovery Technologies), Pharmaron Beijing Co., Ltd., Piramal Enterprises Limited, Thermo Fisher Scientific Inc., Jubilant Pharmova Limited, GenScript Biotech Corporation, Selvita S.A., Shanghai Medicilon Inc., Viva Biotech (Shanghai) Ltd., TCG Lifesciences Pvt Ltd., Shanghai ChemPartner Co., Ltd., Domainex Ltd., NUVISAN Pharma Holding GmbH, Frontage Holdings Corporation, Dalton Pharma Services, Aragen Life Sciences Pvt. Ltd., Promega Corporation
R&D支出の増加、希少疾病とオーファンドラッグに対する研究の取り組み、分析試験サービスのアウトソーシングニーズの高まり
概要
「化学サービスセグメントは、2020年の医薬品発見サービス市場においてタイプセグメントの中で最大のシェアを占めました。」
タイプ別に、創薬サービス市場は化学サービスと生物サービスに分かれています。2020年には化学サービスセグメントがこの市場で最大のシェアを占めていました。この市場セグメントの成長は、堅牢な候補を提供するためのさまざまな初期薬剤開発フェーズにおける化学の広範な適用に起因しています。学術、バイオテクノロジー企業、大手製薬企業における化学の広範な利用も市場の成長を支えています。
「ヒット・ツー・リード同定セグメントは、2020年の医薬品発見サービス市場におけるプロセスセグメントの最大のシェアを占めました。」
プロセスに基づいて、医薬品発見サービス市場は、ターゲット選定、ターゲット検証、ヒットからリードの特定、リードの最適化、候補の検証に広く分類されます。ヒットからリードの特定セグメントは、2020年に医薬品発見サービス市場の最大のシェアを占めました。医薬品発見における重要な役割により、ヒットからリードの特定は最も収益を生むプロセスであり、現在、多くのCROが製薬会社にこれらのサービスを提供。
「腫瘍学セグメントは、2020年の医薬品発見サービス市場における治療領域セグメントで最大のシェアを占めました。」
治療領域に基づいて、薬剤発見サービス市場は、腫瘍学、感染症および免疫系の疾患、神経学、消化器系の疾患、心血管疾患、その他の治療領域に分かれています。腫瘍学は、この市場で最も大きなセグメントであり、これは癌の高い発生率、癌治療薬に関する研究の増加、革新的な癌薬を市場に投入しようとする企業の焦点によるものです。
アメリカ合衆国のラボラトリ・コーポレーション・オブ・アメリカ・ホールディングス、ドイツのユーロフィン・サイエンティフィックSE、アメリカ合衆国のチャールズ・リバー・ラボラトリーズ・インターナショナル・インク、ドイツのエボテックSE、中国のウーシー・アプテック、アメリカ合衆国のファーマシューティカル・プロダクト・ディベロップメントLLC、インドのシンジェーン・インターナショナル・リミテッド、アメリカ合衆国のクリア・グローバル・インク、インドのドクター・レディ・ラボラトリーズ・リミテッド（アウリジェン・ディスカバリー・テクノロジーズ）、中国のファーマロン・北京株式会社、インドのピラマル・エンタープライズ・リミテッド、アメリカ合衆国のサーモ・フィッシャー・サイエンティフィック・インクは、医薬品発見サービス市場で活動する主要企業の一部です。
アジア太平洋：ドラッグディスカバリーサービス市場で最も成長の速い地域
医薬品開発サービス市場は、北米、欧州、アジア太平洋、ラテンアメリカ（LATAM）、中東およびアフリカ（MEA）にセグメント化されています。アジア太平洋地域は、予測期間中に最高のCAGRを記録すると予想されています。この地域での主要な成長要因は、広大な患者人口、新興の中間層、増加する政府支出、および治療領域の専門知識です。世界の製薬企業は、アジアの急成長する市場にアクセスし、製造をこの地域に移すことで生産コストを削減するために、ますますアジアに移行しています。
このレポートのために実施された一次インタビューは、次のように分類できます：
• 回答者による：供給側 70% および需要側 30%
• 役職別：マネージャー - 55%、CXOおよびディレクター層 - 30%、エグゼクティブ - 25%
• 地域別：北米 -20%、ヨーロッパ -10%、アジア太平洋 -55%、その他 -15%
レポートに掲載されている企業の一覧：
・アメリカ合衆国のラボラトリー・コーポレーション・オブ・アメリカ・ホールディングス
• ユーロフィンズ・サイエンティフィック SE（ドイツ）
• チャールズリバーラボラトリーズインターナショナル株式会社 (米国)
エボテック SE（ドイツ）
・ウーシー・アプテック（中国）
- ファーマシューティカルプロダクトディベロップメントLLC（米国）
シンジェンインターナショナルリミテッド（インド）
・キュリア・グローバル株式会社 (米国)
・ドクター・レディ・ラボラトリーズ株式会社（オーリゲン・ディスカバリー・テクノロジーズ）（インド）
ファーマロン北京株式会社 (中国)
ピラマル・エンタープライズ・リミテッド（インド）
・サーモフィッシャーサイエンティフィック社（米国）
ジュビラントファーマヴァ・リミテッド（インド）
・ジェンスクリプトバイオテクコーポレーション（米国）
・セルビタ S.A.（ポーランド）
・上海メディシロン株式会社（中国）
• ビババイオテック（上海）有限公司（中国）
・TCGライフサイエンス株式会社（インド）
上海ケミパートナー株式会社（中国）
・ドメイネックス株式会社（イギリス）
• NUVISANファーマホールディング株式会社（ドイツ）
フロンテージホールディングスコーポレーション (米国)
・ダルトンファーマサービス（カナダ）
アラゲンライフサイエンシズ株式会社（インド）
プロメガコーポレーション（アメリカ）
調査範囲：
この報告書は、薬剤発見市場の詳細な全体像を提供します。この報告書は、製品、用途、最終ユーザーおよび地域などの異なるセグメントにおける市場の規模と将来の成長可能性を推定することを目的としています。また、報告書には主要な市場プレーヤーの競争分析と、彼らの会社プロフィール、最近の進展、重要な市場戦略も含まれています。
報告書購入の主な利点：
この報告書は、市場のリーダーや新規参入者に、全体の薬物発見市場およびそのサブセグメントの収益数値に関する最も近い近似値を提供することで、支援します。また、ステークホルダーが競争環境をよりよく理解し、自社のポジショニングを向上させ、適切な市場進出戦略を立てるための洞察を得る手助けもします。この報告書は、ステークホルダーが市場の動向を理解し、市場の主要なドライバー、制約、課題、トレンド、機会に関する情報を提供することを可能にします。
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 イントロダクション 37
1.1 調査の目的 37
1.2 市場の定義 37
1.2.1 包含・除外事項 37
1.3 市場範囲 38
1.3.1 対象市場 38
1.3.2 調査対象年 38
1.4 通貨 39
1.5 制約 39
1.6 ステークホルダー 39
1.7 変化のサマリー 40
2 調査手法 41
2.1 リサーチデータ 41
2.1.1 二次データ 42
2.1.2 一次データ 42
2.2 市場予測手法 44
2.2.1 一次エキスパート考察 47
2.3 市場成長率予測 48
2.4 市場の内訳とデータのトライアンギュレーション 50
2.5 調査の前提 51
2.6 Covid-19固有の前提 51
2.7 リスク分析 52
3 エグゼクティブサマリー 53
4 更なる考察 57
4.1 ドラッグ・ディスカバリーサービス市場の概要 57
4.2 北米のドラッグディスカバリーサービス市場：薬物タイプ別、国別（2020年） 58
4.3 ドラッグディスカバリーサービスの市場シェア（タイプ別）（2020年 58
4.4 ドラッグ・ディスカバリーサービスの市場、エンドユーザー別 2021年 vs. 2026年（百万米ドル） 59
4.5 ドラッグ・ディスカバリーサービス市場 地域における成長機会 60
5 市場概要 61
5.1 イントロダクション 61
5.2 市場力学 62
5.2.1 促進要因 63
- 5.2.1.1 製薬・バイオ医薬品業界における研究開発費の拡大 63
- 5.2.1.2 分析試験のアウトソーシング需要の増加 64
- 5.2.1.3 希少疾病・オーファンドラッグ研究への取り組み 64
- 5.2.1.4 自社での医薬品開発コストが高い 65
5.2.2 抑制要因 66
- 5.2.2.1 ドラッグディスカバリーや動物の使用に関する規制が厳しい 66
5.2.3 市場機会 67
- 5.2.3.1 COVID-19パンデミックにもかかわらず、医薬品・バイオロジクス市場は成長 67
- 5.2.3.2 エンドユーザーにおける特殊な検査サービスに対する需要の高まり 68
- 5.2.3.3 特許切れ 69
- 5.2.3.4 新興国における高い成長性 69
5.2.4 課題 70
- 5.2.4.1 熟練した人材が不足している 70
5.2.5 市場動向 70
5.3 COVID-19がドラッグディスカバリーサービス市場に与える影響について 73
5.3.1 前提条件 - ドラッグディスカバリーサービス市場の推計と予測 74
5.3.2 前提条件 - 会社の収益成長 75
5.4 レンジ/シナリオ 75
5.5 顧客ビジネスにインパクトを与えるトレンドやディスラプション 76
5.6 バリューチェーン分析 76
5.7 エコシステム分析 77
5.8 技術分析 79
5.9 規制分析 81
5.10 ポーターのファイブフォース分析 83
5.10.1 新規参入の脅威 83
5.10.2 代替品の脅威 83
5.10.3 買い手の交渉力 83
5.10.4 サプライヤーの交渉力 84
5.10.5 競争の激しさ 84
6 ドラッグ・ディスカバリーサービスの市場、プロセス別 85
6.1 イントロダクション 86
6.2 ターゲット選定 86
6.3 ターゲットバリデーション 89
6.4 ヒット・トゥ・リードの同定 91
6.4.1 ヒット・トゥ・リードの同定が市場最大のプロセスセグメント 91
6.5 リードの最適化 93
6.6 候補者バリデーション 96
7 ドラッグ・ディスカバリーサービスの市場、タイプ別 99
7.1 イントロダクション 100
7.2 ケミストリーサービス 100
7.3 バイオロジーサービス 102
7.3.1 ゲノミクスとプロテオミクスの導入が市場の成長を促進 102
8 ドラッグ・ディスカバリーサービスの市場、薬品タイプ別 105
8.1 イントロダクション 106
8.2 低分子医薬品 106
8.3 生物学的製剤 109
9 ドラッグ・ディスカバリーサービスの市場、治療エリア別 112
9.1 イントロダクション 113
9.2 オンコロジー 113
9.3 感染症・免疫系疾患 117
9.3.1 疫病の流行は、創薬活動の活発化を必要とする 117
9.4 神経学 119
9.5 消化器系疾患 122
9.6 循環器系疾患 124
9.7 その他治療エリア 127
10 ドラッグ・ディスカバリーサービスの市場、エンドユーザー別 130
10.1 イントロダクション 131
10.2 製薬会社・バイオテクノロジー企業 131
10.3 学術機関 137
10.4 その他のエンドユーザー 140
11 ドラッグ・ディスカバリーサービスの市場、地域別 142
11.1 イントロダクション 143
11.2 北米 143
11.2.1 米国 147
11.2.2 カナダ 150
11.3 ヨーロッパ 153
11.3.1 ドイツ 156
11.3.2 英国 158
11.3.3 フランス 160
11.3.4 イタリア 162
11.3.5 スペイン 165
11.3.6 その他ヨーロッパ 167
11.4 アジア太平洋 169
11.4.1 中国 173
11.4.2 日本 175
11.4.3 インド 178
11.4.4 韓国 180
11.4.5 その他アジア太平洋 182
11.5 ラテンアメリカ 184
11.5.1 ブラジル 187
11.5.2 その他ラテンアメリカ 189
11.6 中東・アフリカ 191
12 競合情勢 194
12.1 概要 194
12.2 主要企業の成功戦略 195
12.3 市場シェア分析 196
12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 197
12.5 企業評価４象限分類 198
12.5.1 STARS 198
12.5.2 EMERGING LEADERS 198
12.5.3 PERVASIVE PLAYERS 198
12.5.4 PARTICIPANTS 198
12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 200
12.6.1 PROGRESSIVE COMPANIES 200
12.6.2 STARTING BLOCKS 200
12.6.3 RESPONSIVE COMPANIES 200
12.6.4 DYNAMIC COMPANIES 200
12.7 COMPANY SERVICE FOOTPRINT 202
12.8 COMPANY GEOGRAPHIC FOOTPRINT 203
12.9 競合シナリオ 204
12.9.1 サービスローンチ 204
12.9.2 ディール 205
12.9.3 拡大 206
13 企業プロファイル 207
13.1 主要企業 207
13.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS 207
13.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 211
13.1.3 WUXI APPTEC 218
13.1.4 THERMO FISHER SCIENTIFIC 223
13.1.5 PHARMARON BEIJING CO., LTD. 227
13.1.6 EVOTEC SE 232
13.1.7 EUROFINS SCIENTIFIC SE 240
13.1.8 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. 248
13.1.9 PIRAMAL ENTERPRISES LIMITED 250
13.1.10 SYNGENE INTERNATIONAL LIMITED 253
13.1.11 CURIA GLOBAL INC. 257
13.1.12 GENSCRIPT BIOTECH CORPORATION 260
13.1.13 JUBILANT PHARMOVA LIMITED 263
13.1.14 FRONTAGE HOLDINGS CORPORATION 267
13.1.15 SHANGHAI MEDICILON INC. 271
13.1.16 DR. REDDY’S LABORATORIES LTD. (AURIGENE DISCOVERY TECHNOLOGIES) 273
13.2 その他企業 276
13.2.1 SELVITA S.A. (FORMERLY SELVITA CRO S.A.) 276
13.2.2 VIVA BIOTECH (SHANGHAI) LTD. 277
13.2.3 TCG LIFESCIENCES PVT LTD. 278
13.2.4 SHANGHAI CHEMPARTNER CO., LTD. 279
13.2.5 DOMAINEX LTD. 280
13.2.6 NUVISAN PHARMA HOLDING GMBH 281
13.2.7 DALTON PHARMA SERVICES 282
13.2.8 ARAGEN LIFE SCIENCES PVT. LTD. (FORMERLY GVK BIOSCIENCES PVT. LTD.) 283
13.2.9 PROMEGA CORPORATION 284
14 付録 285
14.1 ディスカッションガイド 285
14.2 ナレッジストア : MarketAndMarketのサブスクリプションポータル 289
14.3 可能なカスタマイズ 291
14.4 関連レポート 291
14.5 執筆者の詳細 292
2021 VS.2026（百万米ドル） 53
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
Table of Contents
1 INTRODUCTION 37
1.1 OBJECTIVES OF THE STUDY 37
1.2 MARKET DEFINITION 37
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 37
1.3 MARKET SCOPE 38
1.3.1 MARKETS COVERED 38
1.3.2 YEARS CONSIDERED FOR THE STUDY 38
1.4 CURRENCY 39
1.5 LIMITATIONS 39
1.6 STAKEHOLDERS 39
1.7 SUMMARY OF CHANGES 40
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
2.1.1 SECONDARY DATA 42
2.1.2 PRIMARY DATA 42
2.2 MARKET ESTIMATION METHODOLOGY 44
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 47
2.3 MARKET GROWTH RATE PROJECTIONS 48
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 50
2.5 RESEARCH ASSUMPTIONS 51
2.6 COVID-19 SPECIFIC ASSUMPTIONS 51
2.7 RISK ANALYSIS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHTS 57
4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW 57
4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE AND COUNTRY (2020) 58
4.3 DRUG DISCOVERY SERVICES MARKET SHARE, BY TYPE (2020) 58
4.4 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 59
4.5 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
5 MARKET OVERVIEW 61
5.1 INTRODUCTION 61
5.2 MARKET DYNAMICS 62
5.2.1 DRIVERS 63
- 5.2.1.1 Growing R&D expenditure in the pharma & biopharma industry 63
- 5.2.1.2 Increasing demand for outsourcing analytical testing 64
- 5.2.1.3 Initiatives for research on rare diseases and orphan drugs 64
- 5.2.1.4 High cost of in-house drug development 65
5.2.2 RESTRAINTS 66
- 5.2.2.1 Stringent regulations governing drug discovery and animal usage 66
5.2.3 OPPORTUNITIES 67
- 5.2.3.1 Growth in drugs and biologics market despite COVID-19 pandemic 67
- 5.2.3.2 Rising demand for specialized testing services among end users 68
- 5.2.3.3 Patent expiry 69
- 5.2.3.4 High growth prospects in emerging markets 69
5.2.4 CHALLENGES 70
- 5.2.4.1 Shortage of skilled personnel 70
5.2.5 MARKET TRENDS 70
- 5.2.5.1 Shift in drug discovery services due to growing adoption of AI-based tools 70
- 5.2.5.2 Increased outsourcing to emerging Asian economies 71
- 5.2.5.3 CRO industry consolidation 72
- 5.2.5.4 Integrated end-to-end R&D service solution 73
5.3 IMPACT OF COVID-19 ON THE DRUG DISCOVERY SERVICES MARKET 73
5.3.1 ASSUMPTIONS - DRUG DISCOVERY SERVICES MARKET ESTIMATION AND FORECAST 74
5.3.2 ASSUMPTIONS - COMPANY REVENUE GROWTH 75
5.4 RANGES/SCENARIO 75
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 76
5.6 VALUE CHAIN ANALYSIS 76
5.7 ECOSYSTEM ANALYSIS 77
5.8 TECHNOLOGY ANALYSIS 79
5.9 REGULATORY ANALYSIS 81
5.10 PORTER’S FIVE FORCES ANALYSIS 83
5.10.1 THREAT OF NEW ENTRANTS 83
5.10.2 THREAT OF SUBSTITUTES 83
5.10.3 BARGAINING POWER OF BUYERS 83
5.10.4 BARGAINING POWER OF SUPPLIERS 84
5.10.5 DEGREE OF COMPETITION 84
6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS 85
6.1 INTRODUCTION 86
6.2 TARGET SELECTION 86
6.2.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT THE GROWTH OF THIS MARKET 86
6.3 TARGET VALIDATION 89
6.3.1 RISING NUMBER OF DRUG DISCOVERY RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH 89
6.4 HIT-TO-LEAD IDENTIFICATION 91
6.4.1 HIT-TO-LEAD IDENTIFICATION IS THE LARGEST PROCESS SEGMENT IN THE MARKET 91
6.5 LEAD OPTIMIZATION 93
6.5.1 LEAD OPTIMIZATION REQUIRES STATE-OF-THE-ART INFORMATICS SYSTEMS TO FACILITATE TRANSPARENT PRESENTATION AND ANALYSIS 93
6.6 CANDIDATE VALIDATION 96
6.6.1 FUTURE MANUFACTURING SUITABILITY, SCALE-UP, COMMERCIAL VIABILITY, AND COST-EFFECTIVENESS OF CANDIDATES HEAVILY IMPACT THE LONG-TERM SUCCESS OF DRUGS 96
7 DRUG DISCOVERY SERVICES MARKET, BY TYPE 99
7.1 INTRODUCTION 100
7.2 CHEMISTRY SERVICES 100
7.2.1 GROWING CHEMICAL & BIOCHEMICAL TESTS AND WIDE APPLICATIONS OF CHEMISTRY IN DRUG DISCOVERY ARE MAJOR FACTORS DRIVING MARKET GROWTH 100
7.3 BIOLOGY SERVICES 102
7.3.1 THE INTRODUCTION OF GENOMICS AND PROTEOMICS WILL ENHANCE MARKET GROWTH 102
8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE 105
8.1 INTRODUCTION 106
8.2 SMALL-MOLECULE DRUGS 106
8.2.1 INCREASING NUMBER OF START-UPS AND NEW ENTRANTS IN THE SMALL-MOLECULE DRUGS SEGMENT WILL DRIVE THE GROWTH OF THIS MARKET 106
8.3 BIOLOGIC DRUGS 109
8.3.1 SAFETY AND MANUFACTURING CHALLENGES ASSOCIATED WITH BIOLOGICS DEVELOPMENT TO DRIVE ADOPTION OF OUTSOURCING SERVICES 109
9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA 112
9.1 INTRODUCTION 113
9.2 ONCOLOGY 113
9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH 113
9.3 INFECTIOUS & IMMUNE SYSTEM DISEASES 117
9.3.1 EPIDEMIC OUTBREAKS NECESSITATE INCREASING DRUG DISCOVERY ACTIVITIES 117
9.4 NEUROLOGY 119
9.4.1 THE INCREASING NUMBER OF PATIENTS SUFFERING FROM NEUROLOGICAL DISORDERS IS DRIVING MARKET GROWTH 119
9.5 DIGESTIVE SYSTEM DISEASES 122
9.5.1 LARGE POPULATION SEEKING EFFECTIVE REMEDIES FOR DIGESTIVE DISEASES IS EXPECTED TO DRIVE THE MARKET 122
9.6 CARDIOVASCULAR DISEASES 124
9.6.1 THE HIGH GLOBAL BURDEN OF CARDIOVASCULAR DISEASES HAS INCREASED THE FOCUS ON DEVELOPING EFFECTIVE DRUGS 124
9.7 OTHER THERAPEUTIC AREAS 127
10 DRUG DISCOVERY SERVICES MARKET, BY END USER 130
10.1 INTRODUCTION 131
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 131
10.2.1 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE 134
10.2.2 TIER 1 COMPANIES 134
- 10.2.2.1 High investing capacity is the major factor driving the growth of this segment 134
10.2.3 TIER 2 COMPANIES 136
- 10.2.3.1 Limited investment capacity is expected to restrain the growth of this segment 136
10.2.4 TIER 3 COMPANIES 136
- 10.2.4.1 Tier 3 companies are smaller and have fewer technical advantages 136
10.3 ACADEMIC INSTITUTES 137
10.3.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT 137
10.4 OTHER END USERS 140
11 DRUG DISCOVERY SERVICES MARKET, BY REGION 142
11.1 INTRODUCTION 143
11.2 NORTH AMERICA 143
11.2.1 US 147
- 11.2.1.1 Availability of advanced R&D infrastructure has driven the growth of the US market 147
11.2.2 CANADA 150
- 11.2.2.1 Preference of pharmaceutical companies to conduct clinical trials in Canada to support market growth 150
11.3 EUROPE 153
11.3.1 GERMANY 156
- 11.3.1.1 Government support and flexible labor laws are driving the growth of the German drug discovery services market 156
11.3.2 UK 158
- 11.3.2.1 Collaborations between the government and private stakeholders to support market growth 158
11.3.3 FRANCE 160
- 11.3.3.1 The high number of oncology research projects in France to drive market growth 160
11.3.4 ITALY 162
- 11.3.4.1 High number of clinical trials and the low drug approval time are the major factors driving market growth 162
11.3.5 SPAIN 165
- 11.3.5.1 Short study start-up times and rising R&D expenditure to boost the growth of the Spanish market 165
11.3.6 REST OF EUROPE 167
11.4 ASIA PACIFIC 169
11.4.1 CHINA 173
- 11.4.1.1 China dominates the Asia Pacific market due to a robust pharmaceutical industry and the presence of prominent CROs 173
11.4.2 JAPAN 175
- 11.4.2.1 Government initiatives for drug innovation to support market growth in Japan 175
11.4.3 INDIA 178
- 11.4.3.1 Low-cost services and availability of skilled workforce and strong government support to drive market growth in India 178
11.4.4 SOUTH KOREA 180
- 11.4.4.1 Government initiatives and growing R&D activities for drug development to drive market growth 180
11.4.5 REST OF ASIA PACIFIC 182
11.5 LATIN AMERICA 184
11.5.1 BRAZIL 187
- 11.5.1.1 The presence of a large pool of treatment-naïve patients and short approval timeline is expected to drive market growth in this region 187
11.5.2 REST OF LATIN AMERICA 189
11.6 MIDDLE EAST & AFRICA 191
11.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH IN THE MIDDLE EAST AND AFRICA 191
12 COMPETITIVE LANDSCAPE 194
12.1 OVERVIEW 194
12.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN 195
12.3 MARKET SHARE ANALYSIS 196
12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 197
12.5 COMPANY EVALUATION QUADRANT 198
12.5.1 STARS 198
12.5.2 EMERGING LEADERS 198
12.5.3 PERVASIVE PLAYERS 198
12.5.4 PARTICIPANTS 198
12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 200
12.6.1 PROGRESSIVE COMPANIES 200
12.6.2 STARTING BLOCKS 200
12.6.3 RESPONSIVE COMPANIES 200
12.6.4 DYNAMIC COMPANIES 200
12.7 COMPANY SERVICE FOOTPRINT 202
12.8 COMPANY GEOGRAPHIC FOOTPRINT 203
12.9 COMPETITIVE SCENARIO 204
12.9.1 SERVICE LAUNCHES 204
12.9.2 DEALS 205
12.9.3 EXPANSIONS 206
13 COMPANY PROFILES 207
13.1 KEY PLAYERS 207
13.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS 207
13.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 211
13.1.3 WUXI APPTEC 218
13.1.4 THERMO FISHER SCIENTIFIC 223
13.1.5 PHARMARON BEIJING CO., LTD. 227
13.1.6 EVOTEC SE 232
13.1.7 EUROFINS SCIENTIFIC SE 240
13.1.8 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. 248
13.1.9 PIRAMAL ENTERPRISES LIMITED 250
13.1.10 SYNGENE INTERNATIONAL LIMITED 253
13.1.11 CURIA GLOBAL INC. 257
13.1.12 GENSCRIPT BIOTECH CORPORATION 260
13.1.13 JUBILANT PHARMOVA LIMITED 263
13.1.14 FRONTAGE HOLDINGS CORPORATION 267
13.1.15 SHANGHAI MEDICILON INC. 271
13.1.16 DR. REDDY’S LABORATORIES LTD. (AURIGENE DISCOVERY TECHNOLOGIES) 273
13.2 OTHER COMPANIES 276
13.2.1 SELVITA S.A. (FORMERLY SELVITA CRO S.A.) 276
13.2.2 VIVA BIOTECH (SHANGHAI) LTD. 277
13.2.3 TCG LIFESCIENCES PVT LTD. 278
13.2.4 SHANGHAI CHEMPARTNER CO., LTD. 279
13.2.5 DOMAINEX LTD. 280
13.2.6 NUVISAN PHARMA HOLDING GMBH 281
13.2.7 DALTON PHARMA SERVICES 282
13.2.8 ARAGEN LIFE SCIENCES PVT. LTD. (FORMERLY GVK BIOSCIENCES PVT. LTD.) 283
13.2.9 PROMEGA CORPORATION 284
14 APPENDIX 285
14.1 DISCUSSION GUIDE 285
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 289
14.3 AVAILABLE CUSTOMIZATIONS 291
14.4 RELATED REPORTS 291
14.5 AUTHOR DETAILS 292
2021 VS. 2026 (USD MILLION) 53
TABLE 1 DRUG DISCOVERY AND DEVELOPMENT PROCESS OVERVIEW TABLE 2 DRUG DISCOVERY SERVICES MARKET: IMPACT ANALYSIS TABLE 3 LIST OF BIOLOGICS APPROVALS BY US FDA, 2020 TABLE 4 US: BIOLOGICS GOING OFF-PATENT DURING 2018-2025 TABLE 5 LIST OF ACQUISITIONS TABLE 6 SUPPLY CHAIN ECOSYSTEM TABLE 7 REGULATORY SCENARIO TABLE 8 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS TABLE 9 DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 10 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2019-2026 (USD MILLION) TABLE 11 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 12 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION TABLE 13 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 14 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 15 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2019-2026 (USD MILLION) TABLE 16 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 17 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION TABLE 18 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 19 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 20 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION TABLE 21 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 22 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 23 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 24 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 25 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2019-2026 (USD MILLION) TABLE 26 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 27 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION TABLE 28 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 29 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 30 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION TABLE 31 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 32 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 33 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 34 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 35 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION) TABLE 36 CHEMISTRY SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION) TABLE 37 NORTH AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY TABLE 38 EUROPE: CHEMISTRY SERVICES MARKET, BY COUNTRY TABLE 39 APAC: CHEMISTRY SERVICES MARKET, BY COUNTRY TABLE 40 LATIN AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY TABLE 41 BIOLOGY SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION) TABLE 42 NORTH AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY TABLE 43 EUROPE: BIOLOGY SERVICES MARKET, BY COUNTRY TABLE 44 APAC: BIOLOGY SERVICES MARKET, BY COUNTRY TABLE 45 LATIN AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY TABLE 46 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 47 DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS TABLE 48 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 49 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 50 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 51 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 52 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2019-2026 (USD MILLION) TABLE 53 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 54 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS TABLE 55 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 56 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 57 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA TABLE 58 LIST OF FDA-APPROVED DRUGS FOR ONCOLOGY (2020) TABLE 59 ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION TABLE 60 ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY TABLE 61 EUROPE: ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 62 ASIA PACIFIC: ONCOLOGY DRUG DISCOVERY SERVICES MARKET TABLE 63 LATIN AMERICA: ONCOLOGY DRUG DISCOVERY SERVICES MARKET TABLE 64 INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION) TABLE 65 NORTH AMERICA: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 66 EUROPE: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 67 ASIA PACIFIC: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 68 LATIN AMERICA: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 69 MEDICINES IN DEVELOPMENT FOR NEUROGENERATIVE DISEASES (2021) TABLE 70 NEUROLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION TABLE 71 NORTH AMERICA: NEUROLOGY DRUG DISCOVERY SERVICES MARKET TABLE 72 EUROPE: NEUROLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 73 ASIA PACIFIC: NEUROLOGY DRUG DISCOVERY SERVICES MARKET TABLE 74 LATIN AMERICA: NEUROLOGY DRUG DISCOVERY SERVICES MARKET TABLE 75 DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET TABLE 76 NORTH AMERICA: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 77 EUROPE: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 78 ASIA PACIFIC: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 79 LATIN AMERICA: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 80 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020) TABLE 81 CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET TABLE 82 NORTH AMERICA: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 83 EUROPE: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 84 ASIA PACIFIC: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 85 LATIN AMERICA: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 86 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS TABLE 87 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 88 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 89 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 90 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 91 DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 92 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019-2026 (USD MILLION) TABLE 93 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY TABLE 94 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 95 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 96 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY TABLE 97 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION) TABLE 98 TOP PHARMA COMPANIES BY 2020 REVENUE TABLE 99 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2019-2026 (USD MILLION) TABLE 100 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TABLE 101 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2019-2026 (USD MILLION) TABLE 102 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TABLE 103 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2019-2026 (USD MILLION) TABLE 104 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TABLE 105 DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES TABLE 106 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 107 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 108 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 109 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 110 DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS TABLE 111 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 112 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS TABLE 113 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 114 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TABLE 115 DRUG DISCOVERY SERVICES MARKET, BY REGION TABLE 116 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION) TABLE 117 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019-2026 (USD MILLION) TABLE 118 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 119 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019-2026 (USD MILLION) TABLE 120 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION) TABLE 121 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION) TABLE 122 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE TABLE 123 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 124 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 125 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 126 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA TABLE 127 US: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 128 US: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION) TABLE 129 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 130 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 131 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 132 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION) TABLE 133 CANADA: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 134 CANADA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION) TABLE 135 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY TABLE 136 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 137 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 138 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 139 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION) TABLE 140 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 141 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION) TABLE 142 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 143 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 144 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 145 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION) TABLE 146 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 147 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 148 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 149 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 150 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA TABLE 151 UK: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 152 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 153 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 154 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 155 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION) TABLE 156 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 157 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021) TABLE 158 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 159 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 160 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 161 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA TABLE 162 ITALY: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 163 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 164 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 165 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 166 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION) TABLE 167 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 168 ROE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 169 ROE: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 170 ROE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 171 ROE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA TABLE 172 ROE: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 173 APAC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY TABLE 174 APAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 175 APAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 176 APAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 177 APAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA TABLE 178 APAC: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 179 APAC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION) TABLE 180 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 181 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 182 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 183 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION) TABLE 184 CHINA: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 185 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 186 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 187 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 188 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION) TABLE 189 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 190 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 191 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 192 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 193 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA TABLE 194 INDIA: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 195 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 196 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 197 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 198 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION) TABLE 199 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 200 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 201 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 202 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 203 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION) TABLE 204 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 205 LATAM: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY TABLE 206 LATAM: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 207 LATAM: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 208 LATAM: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 209 LATAM: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION) TABLE 210 LATAM: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 211 LATAM: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION) TABLE 212 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 213 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 214 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 215 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION) TABLE 216 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 217 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 218 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 219 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 220 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION) TABLE 221 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 222 MEA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS TABLE 223 MEA: DRUG DISCOVERY SERVICES MARKET, BY TYPE TABLE 224 MEA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE TABLE 225 MEA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA TABLE 226 MEA: DRUG DISCOVERY SERVICES MARKET, BY END USER TABLE 227 MEA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019-2026 (USD MILLION) TABLE 228 DRUG DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION TABLE 229 PRODUCT PORTFOLIO ANALYSIS: DRUG DISCOVERY TABLE 230 GEOGRAPHIC REVENUE MIX: DRUG DISCOVERY SERVICES MARKET (2020) TABLE 231 SERVICE LAUNCHES TABLE 232 DEALS TABLE 233 EXPANSIONS TABLE 234 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW TABLE 235 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW TABLE 236 WUXI APPTEC: BUSINESS OVERVIEW TABLE 237 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW TABLE 238 PHARMARON BEIJING CO., LTD.: BUSINESS OVERVIEW TABLE 239 EVOTEC SE: BUSINESS OVERVIEW TABLE 240 EUROFINS SCIENTIFIC SE: BUSINESS OVERVIEW TABLE 241 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.: BUSINESS OVERVIEW TABLE 242 PIRAMAL ENTERPRISES LIMITED: BUSINESS OVERVIEW TABLE 243 SYNGENE INTERNATIONAL LIMITED: BUSINESS OVERVIEW TABLE 244 CURIA GLOBAL INC.: BUSINESS OVERVIEW TABLE 245 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW TABLE 246 JUBILANT PHARMOVA LIMITED: BUSINESS OVERVIEW TABLE 247 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW TABLE 248 SHANGHAI MEDICILON INC.: BUSINESS OVERVIEW TABLE 249 DR. REDDY’S LABORATORIES LTD.: BUSINESS OVERVIEW
FIGURE 1 RESEARCH DESIGN FIGURE 2 DRUG DISCOVERY SERVICES MARKET: BREAKDOWN OF PRIMARIES FIGURE 3 DRUG DISCOVERY SERVICES MARKET SIZE ESTIMATION FIGURE 4 MARKET SIZE ESTIMATION: APPROACH FIGURE 5 ILLUSTRATIVE EXAMPLE OF COMPANY REVENUE ANALYSIS, 2020 FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES FIGURE 7 DRUG DISCOVERY SERVICES MARKET (SUPPLY-SIDE): CAGR PROJECTIONS FIGURE 8 DRUG DISCOVERY SERVICES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS FIGURE 9 DATA TRIANGULATION METHODOLOGY FIGURE 10 DRUG DISCOVERY SERVICES MARKET, BY TYPE FIGURE 11 DRUG DISCOVERY SERVICES MARKET, BY PROCESS FIGURE 12 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA FIGURE 13 DRUG DISCOVERY SERVICES MARKET, BY END USER FIGURE 14 GEOGRAPHICAL SNAPSHOT OF THE DRUG DISCOVERY SERVICES MARKET FIGURE 15 INCREASING R&D EXPENDITURE IN THE PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY WILL DRIVE MARKET GROWTH FIGURE 16 SMALL-MOLECULE DRUGS ACCOUNTED FOR THE LARGEST SHARE FIGURE 17 CHEMISTRY SERVICES SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2020 FIGURE 18 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES WILL CONTINUE TO DOMINATE THE MARKET IN 2026 FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER THE HIGHEST GROWTH IN THE DRUG DISCOVERY SERVICES MARKET FROM 2021 TO 2026 FIGURE 20 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FIGURE 21 RISING GLOBAL PHARMACEUTICAL R&D SPENDING, 2012-2026 FIGURE 22 ACTIVE PHARMACEUTICAL PIPELINE, 2011-2021 FIGURE 23 NUMBER OF ORPHAN INDICATIONS APPROVED IN THE US (2010-2019) FIGURE 24 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010-2020 (USD BILLION) FIGURE 25 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001-2020) FIGURE 26 DRUG DISCOVERY SERVICES MARKET SCENARIO WITH AND FIGURE 27 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE DRUG DISCOVERY SERVICES MARKET FIGURE 28 REVENUE SHIFT & NEW POCKETS FOR DRUG DISCOVERY SERVICE PROVIDERS FIGURE 29 VALUE CHAIN ANALYSIS OF DRUG DISCOVERY SERVICES MARKET: FIGURE 30 ECOSYSTEM ANALYSIS: DRUG DISCOVERY SERVICES MARKET FIGURE 31 INCIDENCE OF MAJOR TYPES OF CANCER CASES WORLDWIDE (2020) FIGURE 32 PHRMA MEMBER COMPANY R&D EXPENDITURE, 2017-2020 (USD BILLION) FIGURE 33 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT FIGURE 34 US CONTINUES TO DOMINATE THE DISTRIBUTION OF R&D COMPANIES FIGURE 35 APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT FIGURE 36 KEY PLAYERS STRATEGIES IN THE DRUG DISCOVERY SERVICES MARKET, 2019-2021 FIGURE 37 DRUG DISCOVERY SERVICES MARKET: MARKET SHARE ANALYSIS FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN THE DRUG DISCOVERY MARKET, 2018-2020 FIGURE 39 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION FIGURE 40 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION FIGURE 41 LABORATORY CORPORATION OF AMERICA HOLDINGS: FIGURE 42 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: FIGURE 43 WUXI APPTEC: COMPANY SNAPSHOT (2020) FIGURE 44 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT (2020) FIGURE 45 PHARMARON BEIJING CO., LTD.: COMPANY SNAPSHOT (2020) FIGURE 46 EVOTEC SE: COMPANY SNAPSHOT (2020) FIGURE 47 EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT (2020) FIGURE 48 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.: FIGURE 49 PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2020) FIGURE 50 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2020) FIGURE 51 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2020) FIGURE 52 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2020) FIGURE 53 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020) FIGURE 54 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2020)
